Background Patients with relapsed or refractory (RR) multiple myeloma (MM) or Non-Hodgkin’s lymphoma (NHL) have poor outcomes, with overall survival generally less than 12 months after best available therapies. More effective and tolerable treatments are needed. IDP-023 is an allogeneic natural killer cell product. By natural epigenetic reprogramming, g-NK cells are FceR1g-negative and exhibit much… Continue reading 1483 Activity of IDP-023 allogeneic g-NK cells without antibody targeting in first-in-human phase 1/2 study in patients with advanced multiple myeloma or non-hodgkin lymphoma
Tag: Nucleic Acid Biochemistry
1497 Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
Background Systemic activation of multiple immune receptors, such as Toll-like (TLR), Nucleotide Oligomerization Domain (NOD) like, and Stimulator of Interferon Genes (STING) may be required for efficient anti-tumor immune responses. Decoy20 is an attenuated, killed, non-pathogenic, bacterial product with ~90% reduction of lipopolysaccharide (LPS)-endotoxin (TLR4 agonist) activity to enhance intravenous (IV) safety, also containing TLR1/2,2/6,8,9,… Continue reading 1497 Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
76 A novel method for antibody labeling using Proteintech FlexAble kits
Background Multiplex immunostaining has become an increasingly important approach in current biomedical research. However, the availability of directly labeled primary antibodies often poses a bottleneck for multiplex methods. Here we aimed to develop an antibody-labeling process that enables fast and easy conjugation of primary antibodies to fluorophores at a microgram to milligram scale, e.g. for… Continue reading 76 A novel method for antibody labeling using Proteintech FlexAble kits
1333 Epigenetic targeting of PRC2 complexes upregulates MHC-associated pathways and increases immunogenicity in neoplastic and preneoplastic colon tumor cells
Background Low tumor immunogenicity is associated with cancer immune escape, immunotherapy resistance, and poor patient survival.1–3Major histocompatibility complex (MHC) antigen presentation pathways (APPs) play a crucial role in promoting tumor T-cell recognition and initiating antitumoral immune responses. Epigenetic silencing of MHC APPs is a common mechanism leading to tumor progression and immune evasion in gastrointestinal… Continue reading 1333 Epigenetic targeting of PRC2 complexes upregulates MHC-associated pathways and increases immunogenicity in neoplastic and preneoplastic colon tumor cells
1361 Revolutionizing epigenomic analysis in cancer: high-resolution spatial CUT&Tag and spatial ATAC-seq mapping at the single-nucleus level
Background Advances in spatial transcriptomics and proteomics have enabled increasingly complex investigations into gene expression across various cellular subtypes and tissues.1–3 However, these methods do not explore the epigenome, which regulates gene expression in a cell-specific manner and plays a critical role in human diseases including cancer. A nuanced understanding of epigenetic dysregulation of chromatin… Continue reading 1361 Revolutionizing epigenomic analysis in cancer: high-resolution spatial CUT&Tag and spatial ATAC-seq mapping at the single-nucleus level
1394 Transcriptionally distinct subset of TP53 mutant AMLs characterized by sensitivity to JAK inhibition and an inflamed tumor microenvironment
Background TP53 mutant AMLs are a clinically distinctive group of AMLs often associated with poor clinical outcome and resistance to conventional chemotherapy.1 While infrequent in de novo AMLs, they are more frequent in older patients and therapy related AMLs.1 TP53 mutations are also associated with venetoclax (VEN) resistance, which is often used to treat older… Continue reading 1394 Transcriptionally distinct subset of TP53 mutant AMLs characterized by sensitivity to JAK inhibition and an inflamed tumor microenvironment
1360 Controlled epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma promotes T-cell recruitment
Background Despite improved therapeutic outcomes for cancer patients with the advent of immunotherapy, not all patients respond to these agents. Some patients exhibit an ‘immune-cold’ or ‘excluded’ phenotype, with little to no infiltration of T cells into the tumor body. Lack of T-cell infiltration may result from an absence of T-cell recruiting chemokines in the… Continue reading 1360 Controlled epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma promotes T-cell recruitment
1257 Linking fecal microbiota transplant (FMT) to anti-PD-1 response in melanoma using strain-resolved metagenomics
Background The gut microbiome’s role as a determinant of response to immune checkpoint inhibitors (ICI) has ignited interest in fecal microbiota transplantation (FMT) to augment clinical outcomes in advanced melanoma. Initial clinical trials suggest that FMT plus ICI could enhance the efficacy of treatment, including among previously ICI resistant patients. This study sought to identify… Continue reading 1257 Linking fecal microbiota transplant (FMT) to anti-PD-1 response in melanoma using strain-resolved metagenomics
1277 Unique microbial signatures are associated with clinical outcomes of metastatic melanoma after immune checkpoint blockade (ICI) therapy
Background There has been mounting evidence supporting the importance of the tumor microenvironment (TME) in oncogenesis1 and treatment outcomes2 in many malignancies. In the era of immuno-oncologic agents and multimodal therapy for metastatic melanoma,3 4 the TME has immense relevance in guiding systemic and local treatment options. In this study, the TME of patients status-post… Continue reading 1277 Unique microbial signatures are associated with clinical outcomes of metastatic melanoma after immune checkpoint blockade (ICI) therapy
1143 CART cell function improves with IL-4 pathway editing
Background Chimeric antigen receptor T (CART) cell therapy has resulted in impressive overall response rates in the treatment of cancer.1 However, the durable response to therapy is limited by the development of exhaustion which impairs CART cell expansion and persistence.2 Previously, our group identified IL-4 as a regulator of CART cell exhaustion through an evaluation… Continue reading 1143 CART cell function improves with IL-4 pathway editing